Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 4/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25407159 | 0.88 | LMNA (0.44) | LMNAALDH1A1NPSR1L3MBTL1TP53 | |
| SCHEMBL29418000 | 0.86 | TP53 (0.54) | LMNAALDH1A1NPSR1L3MBTL1TP53 | |
| SCHEMBL25211552 | 0.86 | TP53 (0.54) | LMNAALDH1A1NPSR1L3MBTL1TP53 | |
| SCHEMBL25217469 | 0.86 | ALDH1A1 (0.41) | LMNAALDH1A1NPSR1L3MBTL1RXRA | |
| SCHEMBL25215864 | 0.82 | ALDH1A1 (0.48) | LMNAALDH1A1NPSR1L3MBTL1TP53 | |
| SCHEMBL15786415 | 0.80 | NOTUM (0.54) | LMNAALDH1A1L3MBTL1RXRAGRIN1 | |
| SCHEMBL25213647 | 0.79 | ALDH1A1 (0.48) | LMNAALDH1A1NPSR1L3MBTL1KCNH2 | |
| SCHEMBL25407987 | 0.79 | TP53 (0.60) | LMNATP53 | |
| SCHEMBL6541068 | 0.75 | NOTUM (0.46) | LMNAALDH1A1L3MBTL1RXRAGRIN1 | |
| SCHEMBL25218290 | 0.74 | CYP1A2 (0.60) | LMNAALDH1A1NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4188542-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | Global Blood Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022031735-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | PKM, PDK1, PDK2 | LMNA 679/4885ALDH1A1 1945/4885NPSR1 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.